From egg to bioreactor: new trends in vaccine manufacture

White paper explains how recent developments in analytical sensor technology lead to improved process reliability

Increasing demand and the need for shorter development times are convincing vaccine manufacturers to switch from traditional egg-based production to advanced mammalian cell-culture fermentation.

Efficient fermentation requires careful monitoring and control of analytical parameters such as pH and dissolved oxygen.

In a new white paper 'From Egg to Bioreactor', Mettler Toledo explains the change in vaccine production and how recent developments in analytical sensor technology lead to improved process reliability in cell culturing.

Download the free white paper at www.mt.com/uk-vaccine.

Companies